Previous 10 | Next 10 |
Global Blood Therapeutics ' (NASDAQ: GBT) stock rose by more than 8.2% on Wednesday as of 2:40 p.m. ET on news that the company initiated a phase 2/3 clinical trial for its candidate called GBT601, which is being developed to treat sickle cell disease. The trial will be the biotech'...
Global Blood Therapeutics ( NASDAQ: GBT ) said on Wednesday it had begun the Phase 2 portion of a Phase 2/3 trial of its drug candidate GBT601, to treat sickle cell disease. The drug, GBT601, is a sickle hemoglobin (HbS) polymerization inhibitor and works by ...
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle h...
Biotechnology exchange traded funds look to build upon their winning streak on Friday as investors observed a double-digit performance jump across a handful of popular funds over the past week. Healthcare as a sector has been the best performing S&P segment of the market over the past wee...
In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU. There are also adult campaigns in other countries outside of the USA. Two promis...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event. For further details see: Global Blood Therapeutics (GBT) Presents at the William Blair 42nd Annual Growth Stock Conference - Slideshow
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced a new partnership with New York Jets running back Tevin Coleman and his wife, Akilah, whose 4-year-old daughter lives with sickle cell disease (SCD), with ...
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results from the S ickle Cell H ealth A wareness, P erspectives and E xperiences (SHAPE) survey, a multinational survey on the burden o...
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid brewing economic concerns, investors seeking upside opportunities in the equities sector should consider biotech stocks to buy for one simple reason: extraordinary and permanent relevance. No matter what happens to the...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...